Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
In this study the investigators would like to test the hypothesis that in diabetic patients
discharged from the hospital, SoloSTAR Glargine insulin will be superior to syringe-injected
Glargine in terms of diabetes control, compliance, and patient satisfaction and preference.
The investigators will test this hypothesis in a randomized, crossover trial.